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ABSTRACT
Vascular endothelial growth factor-C (VEGF-C)-induced lymphangiogenesis 
and increased tissue drainage have been reported to inhibit acute and chronic 
inflammation, and an activated lymphatic endothelium might mediate peripheral 
tolerance. Using transgenic mice overexpressing VEGF-C in the skin, we found 
that under inflammatory conditions, VEGF-C-mediated expansion of the cutaneous 
lymphatic network establishes an immune-inhibitory microenvironment characterised 
by increased regulatory T (Treg) cells, immature CD11c+CD11b+ dendritic cells 
(DCs) and CD8+ cells exhibiting decreased effector function. Strikingly, lymphatic 
endothelial cell (LEC)-conditioned media (CM) potently suppress DC maturation 
with reduced expression of MHCII, CD40, and IL-6, and increased IL-10 and CCL2 
expression. We identify an imbalance in prostaglandin synthase expression after LEC 
activation, favoring anti-inflammatory prostacyclin synthesis. Importantly, blockade 
of LEC prostaglandin synthesis partially restores DC maturity. LECs also produce 
TGF-ß1, contributing to the immune-inhibitory microenvironment. This study identifies 
novel mechanisms by which the lymphatic endothelium modulates cellular immune 
responses to limit inflammation.
INTRODUCTION
The lymphatic vascular system plays a key role in 
the transport of interstitial fluid, antigens and immune 
cells from the periphery to lymph nodes where adaptive 
immune responses are generated. Expansion of the 
lymphatic network is observed in numerous inflammatory 
conditions [1-3], and transgenic overexpression or 
intradermal injection of the lymphangiogenic factor 
vascular endothelial growth factor (VEGF)-C inhibits 
acute and chronic skin inflammation [4-8]. Similarly, 
viral VEGF-C administration reduced joint lesion severity 
in chronically inflamed arthritic joints [9] and provided 
protection against experimental inflammatory bowel 
disease [10], whereas blockade of VEGFR3 signaling 
aggravated inflammatory bowel disease [11]. Enhanced 
lymphatic drainage function has been implicated as 
the primary mechanism underlying these potent anti-
inflammatory effects of VEGF-C. However, VEGF-C may 
also directly attenuate cellular immunity via regulation 
of macrophage plasticity and activation [10, 12, 13]. 
Moreover, activated lymphatic endothelial cells (LECs) 
are involved in the induction of peripheral tolerance 
[14-18] and might play a role in the generation of an 
immunotolerant tumor microenvironment [19]. 
In the present study, we investigated if VEGF-C 
regulates cellular immunity in cutaneous inflammation, 
and whether it acts directly on inflammatory cells or 
indirectly via activation and expansion of the lymphatic 
endothelium, using K14-VEGF-C transgenic mice that 
express human VEGF-C in the skin under control of the 
keratin-14 promoter [20]. These mice have an expansion of 
lymphatic but not blood vessels in the skin [20] and show 
reduced inflammation during chemical skin carcinogenesis 
[21], acute bacterial pathogen-induced skin inflammation 
[8], in response to UVB irradiation, and in oxazolone-
induced delayed-type hypersensensitivity reactions [5]. 
We used the PKC activator 12-O-tetradecanoylphorbol-13-
acetate (TPA) to induce chronic skin inflammation. This 
was based on its ability to induce epidermal hyperplasia 
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[22, 23] and enhance the K14-promoter driven transgene 
expression [21, 24, 25]. We found that VEGF-C-mediated 
expansion of the lymphatic network establishes an 
immune-inhibitory cutaneous microenvironment. VEGF-C 
had no direct effects on dendritic cell (DC) maturation but 
LEC-conditioned media (CM) potently suppressed DC 
maturation, which was partially restored upon blockade 
of LEC prostaglandin synthesis. This study identifies 
a new mechanism by which the expanded lymphatic 
vasculature modulates cellular immune responses and 
limits inflammation.
RESULTS
Reduced antigen-presentation capacity in the 
inflamed skin of VEGFC transgenic mice
Skin lysates from K14-VEGFC mice contained 
VEGF-C protein (Supplementary Figure 1A) whose 
levels were strongly increased under inflammatory 
conditions, confirming efficient transgene expression 
in the skin. VEGF-C levels were also higher in the sera 
of uninflamed and inflamed K14-VEGFC mice than 
in wildtype (WT) littermate controls (Supplementary 
Figure 1B). The lymphatic network in the normal and 
inflamed skin of K14-VEGFC mice was significantly 
expanded, as determined by staining for the lymphatic 
specific marker LYVE-1 (Supplementary Figure 1C and 
1D), which confirmed that the transgenic VEGF-C was 
biologically active. Although dilated, lymphatic vessels in 
K14-VEGFC mice contained button-type junctions that 
were similar to those observed in wildtype mice when 
co-stained for LYVE-1 and VE-cadherin (Supplementary 
Figure 1E). 
We next investigated the effects of VEGF-C 
overexpression on the immune cell infiltrates in inflamed 
skin. No differences in the proportions of CD11b+ cells 
were detected in the normal skin of K14-VEGFC mice 
(Figure 1A), whereas these mice had elevated numbers of 
CD11b+ cells under inflammatory conditions (Figure 1A). 
This was predominantly due to a significant increase in the 
CD11c+CD11b+ DC population (Figure 1B). A slight, but 
not significant increase in CD11b+/F4/80+ macrophages 
and CD11b+/Gr-1+ myeloid derived suppressor cells was 
also observed (Supplementary Figure 1F-1G). 
We next examined the effects of VEGF-C 
overexpression on DC subpopulations. No differences 
in the proportions of CD11c+CD11b+ cells expressing 
high levels of MHCII invariant chain I-A/I-E were 
observed between uninflamed WT mice and K14-VEGFC 
mice, as assessed by flow cytometry (Figure 1C). Under 
inflammatory conditions however, significantly fewer 
CD11c+CD11b+ cells expressed high levels of I-A/I-E 
in the skin of K14-VEGFC mice (Figure 1C). Similarly, 
in the absence of inflammation, no significant differences 
in the levels of co-stimulatory CD80 or CD40 were 
observed in CD11c+CD11b+ I-A/I-Ehi cells (Figure 
1D-1E), whereas under inflammatory conditions, the 
CD11c+CD11b+ I-A/I-Ehi cells in the skin of K14-VEGFC 
mice had significantly reduced levels of co-stimulatory 
CD80 (Figure 1D). CD40 expression was also slightly 
reduced, however this was not statistically significant 
(Figure 1E). Importantly, CD11c+CD11b+ cells in the skin 
of inflamed K14-VEGFC mice expressed significantly 
lower levels of CCR7 (Figure 1F), a key chemokine 
receptor implicated in DC migration to draining lymph 
nodes [26]. 
Inflamed skin of K14-VEGFC mice has elevated 
regulatory T cell numbers
Immature dendritic cells have the ability to prime 
naive T cells to differentiate into Treg cells [27, 28]. Using 
immunofluorescence stains and image quantification, we 
found significantly increased numbers of both CD4+ and 
CD8+ cells in inflamed skin when compared to normal 
skin (Supplementary Figure 1H-1I), but no significant 
differences were observed in WT versus K14-VEGFC 
mice. The numbers of immunosuppressive Tregs, 
quantified via CD4+Foxp3+ co-staining (Figure 1G), were 
significantly higher in K14-VEGFC mice than in WT mice 
(Figure 1H) in inflamed skin. No significant differences 
in the proportions of CD4+, CD8+ or CD4+Foxp3+ cells 
were observed in the thymus (CD4+, CD8+, CD4+CD8+ 
or CD4+Foxp3), spleen, LNs and blood (CD4+, CD8+, or 
CD4+Foxp3), when comparing K14-VEGFC mice with 
WT controls (Supplementary Figure 2A-2E), indicating 
that the differences in the proportions of Foxp3+ cells 
in the skin are due to a local effect and not a result of 
systemic differences between transgenic and WT mice. 
TGF-ß1 is a potent immunomodulatory cytokine 
implicated in the generation of tolerogenic dendritic cells 
[29, 30] and is a critical factor in both the generation and 
maintenance of Tregs [31, 32], and their effector function 
[33, 34]. In untreated skin, no significant differences in 
TGF-ß1 protein levels, determined by ELISA, were 
detected (Figure 1I), whereas after a single treatment with 
TPA, TGF-ß1 was significantly upregulated in the skin of 
K14-VEGFC mice (Figure 1I). Cultured LECs produced 
relatively high levels of TGF-ß1, as determined by ELISA 
of cell culture supernatants (345.0±132.0 pg/mL) (Figure 
1J). TGF-ß1 was not significantly regulated by VEGF-C 
directly; however, it was significantly increased nearly 
3 fold upon stimulation with TPA (909.3±167.2 pg/mL) 
(Figure 1J), suggesting that the expanded and activated 
lymphatic endothelium in VEGFC transgenic mice 
contributed to the tolerogenic milieu via production of 
TGF-ß1. 
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Figure 1: Inflamed skin of K14-VEGFC mice has elevated numbers of immature CD11c+CD11b+ cells and increased 
proportions of regulatory T cells. Flow cytometry was used to determine the proportions of CD11b+ (A) and CD11c+CD11b+ (B)
cells in the skin of control (n = 3 per genotype) and inflamed (n = 4 per genotype) wildtype and K14-VEGFC mice. CD11c+CD11b+ cells 
were also assessed for their expression of I-A/I-E (MHCII) (C), CD80 (D), CD40 (E) and CCR7 (F) (n = 4 per genotype/treatment except 
n = 7 for CCR7 in inflamed K14-VEGFC). Skin sections from wildtype and K14-VEFC control (n = 3 per genotype) and inflamed (n = 
4 per genotype) mice were co-stained for CD4 and Foxp3. Representative fluorescent images for inflamed skin are shown in (G) (Scale 
bar: 100 µm). Left panels: CD4 (red); middle panels: Foxp3 (green); right panels: merged image of CD4, Foxp3, and Hoechst (blue) to 
visualize nuclei. The insert is a magnified region of the merged image as indicated (scale bar: 50 µm). Arrows indicate Foxp3+CD4+ cells. 
Foxp3+CD4+ cells per image were quantified and are shown in (H) (control n = 3, inflamed n = 4). Black bars: wildtype mice. Grey bars: 
K14-VEGFC mice. TGF-β1 protein levels were quantified in the back skin of control and inflamed wildtype (black bars) and K14-VEGFC 
mice (grey bars) (n = 4 per treatment and genotype) by ELISA (I) TGF-β1 protein levels were also quantified in cell culture supernatants 
taken from TPA (20 ng/mL) and recombinant VEGF-C (500 ng/mL) treated lymphatic endothelial cells (J) For all graphs, data shown are 
the mean ± SD. Two-way ANOVA with Bonferroni post-test was used to assess statistical significance except (F) where Student’s t-test was 
applied. *p < 0.05,**p < 0.01.
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Skin-draining lymph nodes of inflamed K14-
VEGFC mice are reduced in size, cellularity and 
effector cell activity
The inguinal LNs of inflamed K14-VEGFC mice 
were significantly smaller than those of inflamed WT 
mice (Figure 2A and 2B). The leukocyte cellularity 
was also significantly reduced (Figure 2C), indicating 
that the inflammatory response was attenuated. Using 
flow cytometry, a significant reduction in the number of 
CD11c+CD11b+ cells was observed in the skin draining 
LNs of inflamed, but not uninflamed, K14-VEGFC 
mice (Figure 2D). Reflecting the findings in the skin, 
CD11c+CD11b+ cells in draining LNs of inflamed K14-
VEGFC mice expressed significantly lower levels of I-A/
I-E, costimulatory CD40 and CCR7 (Figure 2E, 2F and 
2G). 
We next investigated the ability of CD11c+CD11b+ 
cells to migrate from inflamed skin to the skin-draining 
LNs (schematic shown in Figure 2H). Following dermal 
FITC painting, the skin draining LNs of K14-VEGFC 
mice contained significantly fewer FITC+CD11c+CD11b+ 
cells that had migrated from the inflamed dermis (Figure 
2I and 2J). This reduced migration most likely resulted 
from the observed decreased expression of CCR7 on 
CD11c+CD11b+ cells. Alternatively, a deregulated 
CCL21 gradient may also disrupt effective DC trafficking 
to draining LNs. We found that uninflamed and TPA-
treated (single application) skin of K14-VEGFC mice had 
significantly higher levels of CCL21 than WT controls, 
and TPA-treatment significantly increased CCL21 
expression (Supplementary Figure 3A), indicating that 
the normal tissue distribution of CCL21 might be altered 
in K14-VEGFC mice. We also observed increased dermal 
tissue clearance of a lymphatic specific tracer, with a 
reduced tissue half-life time in K14-VEGFC mice when 
compared to wildtype mice (Supplementary Figure 3B). 
This indicates that VEGF-C and the resulting expanded 
lymphatic vasculature led to increased lymph flow, which 
suggests that the observed reduced migration of DCs to 
draining LNs is not due to decreased lymphatic function 
in these mice. Increased flow from inflamed skin could 
however impact upon the dermal inflammatory milieu, 
for example by increasing the drainage of inflammatory 
molecules.
The inflammatory response in skin draining LNs 
is reduced in K14-VEGFC mice
We next investigated other inflammatory cell 
populations within inflammation-draining LNs. Although 
no differences in the proportions of B220+, TCRß+, CD4+ 
and CD8+ cells were observed when comparing WT with 
K14-VEGFC inflamed LNs (Figure 2K), inflammation-
draining LNs of K14-VEGFC mice had significantly 
fewer B220+, TCRß+, CD4+ and CD8+ cells, indicative 
of a reduced inflammatory response (Figure 2L). Since 
migratory activated DCs from sites of inflammation 
present antigens to T cells within draining LNs, the 
activity of T cells within the draining node should reflect 
the frequency and activation status of intra-nodal DCs. We 
therefore isolated CD8+ cells from untreated and inflamed 
mice and examined IFN-γ production following in vitro 
stimulation with PMA/ionomycin. In agreement with our 
observation that draining LNs of K14-VEGFC mice had 
reduced numbers of DCs exhibiting a more immature 
phenotype, inguinal LNs of K14-VEGFC mice contained 
significantly fewer IFN-γ-producing CD8+ cells. These 
differences were not observed in untreated mice or non-
skin-draining (mesenteric) LNs (Figure 2M-2N).
VEGF-C does not directly modulate the 
phenotype of dendritic cells 
We next tested whether DCs express VEGFR3, 
the receptor for VEGF-C. CD11c+BMDCs significantly 
upregulated VEGFR3, and to a lesser extent VEGFR2 and 
VEGFR1, in response to IFN-γ or TPA stimulation (Figure 
3A). However, VEGFC was not chemotactic for control 
or IFN-γ-stimulated BMDCs, whereas CCL21 promoted 
chemotactic migration (Figure 3B). Expression of CD40 
(Figure 3C), CD80 (Figure 3D), and CD86 (Figure 3E) 
was not significantly altered on control, IFN-γ- or TPA-
stimulated BMDCs upon addition of VEGF-C (500 ng/
mL). Similarly, recombinant VEGF-C had no effect on the 
expression of the MHCII invariant chain I-A/I-E (Figure 
3F). The ability of VEGF-C to modulate the expression of 
pro- and anti-inflammatory cytokines (IL-6, IL-10, TNFα) 
(Figure 3G, 3H and 3I), the chemokine CCL2 (Figure 
3J) and the expression of the chemokine receptor CCR7 
(Figure 3K) was also analysed using realtime PCR. In 
unstimulated and IFN-γ- or TPA-stimulated cells, VEGFC 
had very minor to no effects on the expression of these 
genes.
Lymphatic endothelial cell conditioned media 
induce immunosuppressive dendritic cells
As VEGF-C had no direct effect on DC maturation, 
we investigated if LECs might produce factors that 
modulate the phenotype of DCs. BMDCs were treated 
with conditioned media collected from LECs (LEC-CM) 
and cultured with or without IFN-γ. Using flow cytometry, 
these cells were assessed for expression of CD80, CD40, 
CD86, I-A/I-E and CCR7 (Figure 4A-4E). Treatment 
of BMDCs with LEC-CM significantly downregulated 
expression of co-stimulatory CD40 and CD86, reduced 
the expression of I-A/I-E and also significantly reduced 
CCR7 expression. We then analyzed the inflammatory 
cytokine profiles of these DCs using quantitative RT-
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Figure 2: A reduced inflammatory response is observed in skin-draining inguinal LNs of K14-VEGFC mice. Skin-
draining inguinal LNs of untreated and inflamed wildtype and K14-VEGFC mice were harvested. Central transverse sections of inguinal 
LNs were stained for B220 (red) and Hoechst (blue). Representative immunofluorescent images are shown in (A) (Scale bar: 1 mm). LNs 
were weighed (B) and the cellularity determined using a hemocytometer (C) Each data point represents a single lymph node. The horizontal 
line represents the mean. Inguinal LNs from untreated (n = 3 per genotype) and inflamed (n = 4 per genotype) mice were analysed for their 
numbers of CD11c+CD11b+ cells using flow cytometry (D) Proportions of I-A/I-Ehi (E), co-stimulatory CD40hi (F) and CCR7hi (G) cells 
were also quantified on CD11c+CD11b+ cells within inflamed inguinal LNs (n = 4, 4, and 7, respectively). Data are presented as mean ± 
SD. To investigate the ability of CD11c+CD11b+ cells to migrate from inflamed skin to skin-draining LNs, 5% FITC thioglycolate/acetone 
1:1 v/v was applied to the inflamed backskin of wildtype (n = 4) and K14-VEGFC mice (n = 4) see schematic (H) The proportions of 
FITC-positive CD11c+CD11b+ cells in the draining LNs (axillary + inguinal) were quantified by flow cytometry (I) and the total number 
of migrating cells calculated (J) Proportions of B220, TCRβ, CD4 and CD8 positive cells were quantified using flow cytometry in skin-
draining inguinal LNs from inflamed wildtype (n = 3) and K14-VEGFC (n = 3) mice (K) Total cellularity in the lymph node for each marker 
was also quantified and is shown in (L) Leukocytes isolated from inguinal and mesenteric LNs were stimulated with PMA/ionomycin and 
analysed for IFN-γ-production. Representative flow cytometry histograms are shown (M) Proportions of IFN-γ+CD8+ T cells in leukocytes 
isolated from control and inflamed mice are shown (N) (n = 4 per treatment and genotype). All data are presented as mean ± SD. Figures 
B-D were analysed using Two-way ANOVA with Bonferroni’s post-test to assess statistical significance. Student’s t-test was applied to all 
other figures. *p < 0.05,**p < 0.01 ***p < 0.001.
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PCR and found that treatment with LEC-CM also 
significantly reduced the expression of pro-inflammatory 
IL-6 (Figure 4F) when stimulated with IFN-γ. TNF-α 
was also reduced under control and IFN-γ stimulation, 
however, this was not statistically significant (Figure 
4G). Furthermore, LEC-CM significantly upregulated 
the anti-inflammatory cytokine IL-10 (Figure 4H) and 
the chemokine CCL2 (Figure 4I). Collectively, these data 
reveal that LECs produce a factor, or factors, that potently 
induce an immature, less inflammatory phenotype in 
DCs, characterized by a potentially reduced capacity for 
antigen presentation and an anti-inflammatory cytokine 
production profile. Given the observed elevated TGF-ß 
levels in inflamed skin of VEGF-C mice (Figure 1I) and 
the ability of LECs to produce TGF-ß (Figure 1J), we 
investigated if TGF-ß could induce the production of DCs 
with a less mature phenotype. Addition of TGF-ß during 
DC maturation assays had no effect on the expression of 
Figure 3: VEGF-C does not directly modulate the phenotype of CD11c+ cells. Bone marrow derived CD11c+ cells were 
stimulated in vitro for 24 hours with IFN-γ (100 ng/mL) or TPA (10 ng/mL) and assessed for VEGFR expression using quantitative RT-
PCR (A) Data are shown as fold change relative to control treated cells. Control and IFN-γ-stimulated bone marrow derived CD11c+ cells 
were assessed for their ability to migrate towards VEGF-C (500 ng/mL) in an in vitro transwell migration assay (B) The positive control of 
dendritic cell migration towards CCL21 (100 ng/mL) is also shown. Mean number of cells migrated per well (n = 3) is shown ± SD. Bone 
marrow derived CD11c+ cells were stimulated for 24 hours in vitro with IFN-γ (100 ng/mL) or TPA (10 ng/mL) in the presence or absence 
of VEGF-C (500 ng/mL) and were assessed for their expression of CD40 (C), CD80 (D), CD86 (E) and I-A/I-E (F) using flow cytometry. 
Data are shown as mean ± SD. No statistically significant differences were observed when comparing control to VEGF-C treated cells with 
or without IFN-γ or TPA stimulation. mRNA isolated from likewise treated cells were assessed using quantitative real-time PCR for the 
expression of IL-6 (G), TNF-α (H), IL-10 (I), CCL2 (J) and CCR7 (K). Data are shown as the fold change relative to control treated cells. 
Student’s t-test was used to assess statistical significance (Figures B-F). *p < 0.05, **p < 0.01 ***p < 0.001.
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I-A/I-E or CD40 (Supplementary Figure 4). Furthermore, 
addition of TGF-ß signaling inhibitors (LY-364947 
and SB-431542) failed to block the potent maturation 
inhibitory effect of LEC-CM, indicating that TGF-β does 
not play a major role in the LEC-induced inhibition of DC 
maturation (Supplementary Figure 4). 
Blockade of prostaglandin synthesis partially 
reverts LEC-CM effects on dendritic cell function
Prostaglandins are potent modulators of 
inflammation. We next investigated if prostaglandins 
might contribute to the immunosuppressive effects of 
LEC-CM on DCs. BMDCs were cultured with CM 
generated from LECs treated or not with the COX-2 
inhibitor Celecoxib and were analysed using RT-PCR 
and flow cytometry for expression of key cytokines, 
chemokines and surface markers. Blockade of COX-
2 reduced LEC-CM-mediated upregulation of IL-10 
expression in BMDCs by approximately 40% (Figure 
5A) and also reduced LEC-CM-induced upregulation of 
CCL2 expression by approximately 50% (Figure 5B). 
Celecoxib treatment of LECs also partially reversed LEC-
CM-mediated downregulation of CD40 expression on 
the surface of BMDCs (Figure 5C), potentially restoring 
effective antigen presentation function of these cells. 
The generation of specific prostaglandins is 
dependent upon the availability of their respective 
synthases. We analyzed in cultured LECs the expression 
of two downstream prostaglandin synthases, prostacyclin 
(prostaglandin I2, PGI2) synthase (PTGIS) and 
prostaglandin E synthase (PGES). LECs increased the 
expression of PTGIS approximately 3-fold (Figure 5D) 
upon treatment with TPA, and reduced the expression of 
PGES to approximately 40% of that expressed by control 
cells (Figure 5E). In line with this, cultured LECs were 
found to produce prostacyclin (assessed by ELISA of cell 
culture supernatants), and upregulated its production upon 
stimulation with TPA (Figure 5F). Importantly, blockade 
Figure 4: Lymphatic endothelial cell conditioned media induce an immunosuppressive phenotype in bone marrow 
derived CD11c+ cells. Bone marrow derived CD11c+ cells were treated with control media (CTRL-M) or lymphatic endothelial cell-
conditioned media (LEC-CM) for 24 hours with or without IFN-γ stimulation (100 ng/mL). Flow cytometric analysis of their expression 
of CD80 (A), CD40 (B), I-A/I-E (C), CD86 (D) and CCR7 (E) was performed with either the median fluorescence intensity (MFI) or 
percentage of cells expressing high marker levels shown. Data shown are representative of three independent biological replicates. mRNA 
isolated from likewise treated cells was analysed using RT-PCR for the expression of IL-6 (F), TNFα (G), IL-10 (H) and CCL2 (I) Data 
are shown as the mean fold change relative to control treated cells (normalized to 1) of three independent biological replicates. Statistical 
significance was assessed using the Two-way (A-E) and One-Way (F-I) ANOVA with Bonferroni post-tests.. *p < 0.05, **p < 0.01, ***p 
< 0.001.
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Figure 5: Blockade of prostaglandin synthesis partially reverts immunosupressive effects of LEC conditioned media. 
Bone marrow derived CD11c+ cells were treated for 24 hours with either control media (CTRL-M) or lymphatic endothelial cell-conditioned 
media (LEC-CM) that was generated ± Celecoxib (20 µM). BMDCs were stimulated with ± IFN-γ (100 ng/mL) as shown. mRNAs from 
treated cells were then analysed using RT-PCR for the expression of IL-10 (A) and CCL2 (B) Data are shown as the fold change relative to 
control treated cells and are representative of three independent biological replicates. Likewise treated cells were also analysed using flow 
cytometry for their expression of CD40 (C) Data are shown as the median fluorescence intensity and are representative of two biological 
replicates. LECs were stimulated with TPA (10 ng/mL) for 6 hours and the relative expression of prostacyclin synthase (PTGIS) (D) and 
prostaglandin E synthase (PGES) (E) compared to Rplp0 was assessed using real-time PCR. Data are shown as the fold change relative to 
control treated cells (normalized to 1) and are representative of three independent biological replicates. Prostacyclin levels in cell culture 
supernatants were assessed via ELISA. LECs were cultured for 48 hours with or without celecoxib (20 µM) and TPA (10 ng/mL) (F) RT-
PCR of mRNA extracted from the skin of wildtype and K14-VEGFC, control (n = 3) and inflamed (n = 3-4) mice was used to assess the 
relative expression of COX-1 (G), COX-2 (H), PTGIS (I) and PGES (J) when compared to Rplp0. Data are shown as the fold change 
± SD relative to control-treated wildtype mice (normalized to 1). The ratio of the relative expression of PTGIS:PGES is shown in (K)
Representative confocal images of inflamed back skin of wildtype and K14-VEGFC mice, stained for LYVE-1 (red) and PTGIS (green), 
scale bar 50 µm (L) We consistently observed more PTGIS staining in K14-VEGFC skin, both in lymphatic endothelial cells (arrows) and 
non-endothelial cells. Note that lymphatic vessels of similar size were chosen for better comparability of the staining pattern. Student’s 
t-test was used to assess statistical significance in A-C, F and K. Two-way ANOVA with Bonferroni’s post-test was used in G-J. *p < 0.05.
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of prostaglandin synthesis using Celecoxib significantly 
reduced prostacyclin levels in LEC-CM (Figure 5F).
We next investigated the levels of prostaglandin 
synthases in the skin of mice. The relative expression 
levels of COX-1 were largely unchanged following 
inflammation (Figure 5G), whereas COX-2 was strongly 
upregulated in the inflamed skin of WT mice (Figure 
5H). Strikingly, a similar upregulation of COX-2 was not 
observed in the inflamed skin of K14-VEGFC mice with 
expression levels similar to those observed in uninflamed 
skin (Figure 5H). PTGIS expression was not increased in 
inflamed WT mice but was upregulated in the inflamed 
skin of K14-VEGFC mice (Figure 5I). PGES expression 
was comparably expressed in WT and K14-VEGFC 
mice (Figure 5J). In inflamed skin, K14-VEGFC had an 
approximately two fold higher ratio of PTGIS to PGES 
than WT mice (Figure 5K). In accordance with these 
findings, the inflamed skin of K14-VEGFC mice showed 
lymphatic PTGIS staining that was largely absent from the 
skin of inflamed wildtype controls (Figure 5L). Thus, an 
increase in the levels of anti-inflammatory (PTGIS) versus 
pro-inflammatory (PGES) prostaglandin synthases may 
contribute to the immune-inhibitory microenvironment in 
the lymphatic rich skin of VEGF-C transgenic mice.
DISCUSSION
Topical TPA application to the skin induces 
cutaneous inflammation characterized by increased 
vascular permeability, swelling and edema, inducing 
a significant inflammatory cell infiltration within the 
dermis [35-37]. We have previously reported that 
transgenic expression of VEGF-C in the skin, resulting 
Figure 6: Schematic of proposed mechanisms of LEC-mediated dendritic cell modulation. The VEGF-C-mediated 
expansion of the inflammatory lymphatic vessel network results in an immune-inhibitory dermal microenvironment. An imbalance in 
LEC synthesis of prostaglandins, namely a shift towards increased synthesis of the inflammation limiting prostacyclin, concomitant with 
decreased synthesis of the pro-inflammatory PGE2, represents a key mechanism resulting in the generation of immature DCs with an 
anti-inflammatory cytokine profile. These effects are compounded by increased LEC-derived TGF-β1 production. In addition, the dermal 
cellular milieu exhibits elevated numbers of Tregs. Decreased DC maturation is implicated in the generation of CD8+ T cells with a reduced 
ability to produce pro-inflammatory IFN-γ.
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in an expanded dermal lymphatic network, limits acute 
skin inflammation and reduces dermal edema formation 
in response to challenge by oxazolone and UV-B [5]. 
Interestingly, the application of oxazolone to K14-
VEGFC mice revealed a significant increase in CD11b+ 
cells when compared to WT controls [5]. In the current 
study, we have more comprehensively characterized the 
inflammatory infiltrate in response to TPA, and identified 
a new mechanism how LECs contribute to the attenuation 
of inflammation. 
DCs, the major antigen presenting leukocytes, play 
crucial roles in inflammation and immunity. Importantly, 
we found that inflamed skin of K14-VEGFC mice contains 
significantly higher proportions of CD11c+CD11b+ cells 
than WT mice. Although increased in number, these cells 
were less mature, with significantly reduced levels of 
MHCII, co-stimulatory molecules, and CCR7, suggesting 
a naïve, tolerogenic phenotype. A defect in DC migration 
to the draining LNs could result in their accumulation 
in the skin. Indeed, we found that the ability of DCs to 
traffic to draining LNs was severely compromised in 
inflamed skin of K14-VEGFC mice, most likely due to 
their reduced expression of the key migratory chemokine 
receptor CCR7 [26, 38]. 
Clearly, impairment of DC trafficking can severely 
impact upon the successful generation of active immune 
responses. As a result, the inflamed skin-draining LNs 
of K14-VEGFC mice were significantly reduced in 
their weight, size and cellularity when compared with 
inflamed WT LNs. Lymph node resident CD11c+CD11b+ 
cells exhibited reduced antigen presentation capabilities 
with I-A/I-E and CD40 expressed at lower levels when 
compared to those in inflamed WT LNs. Importantly, the 
ability of CD8+ cells in inflamed K14-VEGFC LNs to 
produce IFN-γ upon in vitro stimulation was significantly 
reduced when compared to those isolated from inflamed 
WT mice, indicating that skin-derived DCs were not able 
to activate T-cells efficiently. 
Concomitant with a less activated DC phenotype, 
we also observed an increase in CD4+Foxp3+ Tregs in 
the inflamed skin of K14-VEGFC mice when compared 
to WT controls. This is in line with the reported increase 
of infiltrating Tregs in VEGF-C overexpressing tumour 
models [19]. Tregs play a critical role in the resolution 
of inflammation, suppressing both DC and effector T-cell 
functions (reviewed by [39]). A key immune-regulatory 
cytokine is TGF-ßl, which is produced by multiple cell 
types including Tregs and DCs, and at the same time 
regulates the activity of both these cell types (reviewed 
in [40]). For example, TGF-ß1 skews DCs towards a 
tolerogenic phenotype [29, 41], while also modulating the 
generation and regulatory effects of Tregs [31, 42, 43]. 
Thus, the observed increased levels of TGF-ß1 likely 
contribute to the immune-inhibitory microenvironment 
in the inflamed skin of K14-VEGFC mice. Importantly, 
our data further indicate that LECs are a prominent 
source of TGF-ßl. Given the largely expanded lymphatic 
network that we observed in K14-VEGFC mice under 
inflammatory conditions, it is conceivable that lymphatic-
derived TGF-ßl contributes to immune inhibition in the 
dermis. However, our data suggest that TGF-ßl is not the 
main factor responsible for the immature DC phenotype 
observed in the skin of K14-VEGF-C mice. 
Inhibition of DC maturation has been reported for 
the closely related vascular endothelial growth factor-A 
(VEGF-A) in vitro and in vivo [44, 45]. Given that in the 
presence of elevated VEGF-C DCs were less activated, 
we first hypothesized that, similar to VEGF-A, VEGF-C 
might also exert tolerogenic effects on DCs. However, 
although we found upregulation of VEGFR-3 in DCs, we 
could not find any direct effect of VEGF-C on those cells 
in vitro.
Alternatively, the expanded lymphatic endothelium 
may modulate the maturation of DCs in K14-VEGFC 
mice. Previously, inflamed LECs were found to 
downregulate DC expression of costimulatory CD86 via 
an ICAM-1/Mac-1 dependent adhesive interaction that in 
turn suppressed the ability of DCs to activate T-cells [46]. 
Our data suggests that, in addition to TGF-ß1, LECs may 
produce other factors that modulate DC maturity. Notably, 
when culturing BMDCs in LEC conditioned media, they 
assumed an immature phenotype, reminiscent of the DC 
phenotype in the inflamed skin of K14-VEGFC mice. 
To our knowledge, this is the first time that LEC-derived 
factors have been found to directly impact upon DC 
maturity. Furthermore, LEC-CM also significantly altered 
DC cytokine profiles, with reduced expression of pro-
inflammatory IL-6 and TNF-α following stimulation with 
IFN-γ and simultaneous upregulation of anti-inflammatory 
IL-10. Notably, secretion of IL-10 by DCs drives the 
development of TGF-ß- and IL-10-secreting Tregs, 
providing a positive feedback loop for its induction [47, 
48]. LEC-modulated DCs with an increased expression of 
IL-10 would thus significantly contribute to an immune-
inhibitory microenvironment in K14-VEGFC mice. In 
addition to IL-10, LEC-CM also strongly primed DC for 
the expression of CCL2. CCL2 together with its receptor 
CCR2 is involved in the migration of various immune 
cells, such as monocytes and macrophages [49], effector 
T-cells [50] but also Tregs [51]. This may be an additional 
mechanism whereby increased numbers of Tregs are 
recruited to the inflamed dermis in K14-VEGFC mice. 
Furthermore, exposure of splenic T-cells to recombinant 
CCL2 decreased their ability to produce IFN-γ [52] 
suggesting CCL2 may also inhibit effector T-cells directly. 
One potential class of molecules with powerful 
DC modulatory capabilities are prostaglandins [53, 
54]. Blockade of LEC prostaglandin synthesis using 
celecoxib reduced the anti-inflammatory effects of 
LEC-CM by reducing DC IL-10 and CCL2 expression, 
and partially restoring CD40 expression. To further 
elucidate the mechanisms underlying prostaglandin-
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mediated alterations in DC maturation, we analysed 
the relative expression of two of the key prostaglandin 
synthase enzymes, prostacyclin synthase (PTGIS) 
and prostaglandin E synthase (PGES). In vitro, under 
inflammatory conditions, LECs upregulated PTGIS 
while PGES was downregulated. This finding was 
supported with inflamed LECs significantly upregulating 
prostacyclin production. Prostacyclin limited inflammation 
in in vivo models of viral infection and allergic responses 
[55-57]. More recently, it has been shown that prostacyclin 
analogues decreased proinflammatory cytokine secretion 
(including IL-6 and IL-1ß), upregulated IL-10 production 
and decreased co-stimulatory and MHCII expression on 
DC [53], similar to the effects observed here. Conversely, 
PGE2 is largely considered pro-inflammatory, with PGES
-/- 
mice exhibiting decreased dermal inflammatory responses 
and reduced disease severity in a model of rheumatoid 
arthritis [58, 59]. With regards to DC function, PGE2 
enhanced co-stimulatory molecule and MHCII expression, 
induced proinflammatory cytokine secretion [54], and has 
been shown to augment antigen-specific CD4+ and CD8+ 
T-cell proliferation [60]. Thus, we believe that a shift 
towards the generation of anti-inflammatory prostacyclin, 
together with a decrease in pro-inflammatory PGE2 plays 
a major role in the attenuation of dermal inflammation by 
the lymphatic endothelium. 
In vivo, COX-2 was surprisingly not upregulated 
in the inflamed skin of K14-VEGFC mice compared to 
WT mice. On the other hand, these mice expressed higher 
levels of PTGIS, while PGES expression was equivalent 
between the two genotypes. Functional coupling of PGES 
to COX-2 in preference to COX-1 [61-64] and preferential 
selectivity of PTGIS to COX-1 [65-68] may add an 
additional level of regulation to prostaglandin synthesis. 
Low levels of COX-2 may reduce PGES activity, while 
a concomitant relative increase in PTGIS activity 
would allow anti-inflammatory prostacyclin synthesis 
to dominate. Future studies using a lymphatic specific 
knockout of PGES or PTGIS would help to dissect the 
contribution of this mechanism to the regulatory activity 
of LEC with regard to DC phenotype and inflammation. 
Collectively, this study highlights that in addition to 
enhancing lymphatic drainage by increasing the expansion 
of lymphatic vessels [5, 69, 70], VEGF-C-induced LECs 
also possess immune modulating properties that act to 
reduce inflammation. We have identified LEC-derived 
prostaglandins as a negative modulator of DC maturation 
and anti-inflammatory cytokine production in the skin. 
This effect may be compounded by increased LEC-
derived TGF-ß1 production (Figure 6). As a result, DC 
maturation and CD8+ T-cell activation are inhibited under 
inflammatory conditions in VEGF-C overexpressing mice, 
whereas Tregs are elevated. LEC-mediated immunological 
changes therefore may further impact positively upon 
the resolution of inflammation. Together, these findings 
reveal an unanticipated role of the lymphatic endothelium 
in dampening inflammation via distinct molecular and 
cellular mechanisms.
MATERIALS AND METHODS
Mouse model of TPA-induced inflammation
Chronic dorsal skin inflammation was induced 
in 6-8 week old hemizygous K14-VEGFC [20] and 
littermate WT mice with TPA application (5 µg dissolved 
in acetone 1x/week for 5 weeks). Experimentation was 
undertaken in accordance with protocols approved by the 
Kantonales Veterinäramt Zürich. Tissue for analysis was 
harvested two days after the final TPA treatment. Protein 
was isolated from back skin of known weight as described 
[5]. VEGF-C and TGF-ß1 protein was quantified using 
VEGF-C and TGF-ß1 ELISA Kits (R&D Systems), and 
was normalised to tissue weight and total protein amount 
within the lysate. Immunofluorescence stainings were 
performed using standard techniques as described in the 
Supplementary Methods. Stained sections were examined 
on an Axioscope Mot Plus microscope (Carl Zeiss) 
equipped with an Axiocam MRc camera (Carl Zeiss). 
Images were acquired using Axio-Vision software Version 
4.7.1 (Carl Zeiss). ImageJ was used for image analysis. 
To quantify immune cell infiltration and the area covered 
by lymphatic vessels in the skin of mice, ten images/
skin section/mouse at a 20x magnification were taken. 
Foxp3+CD4+ cells were quantified by manually counting 
double positive cells in skin sections from three control 
and four inflamed mice for each genotype. 
Flow cytometric analysis of tissue samples
Single cell suspensions were prepared from tissues 
and stained as described in the Supplementary Methods. 
Antibodies used are listed in Supplementary Methods 
Table 2. Flow cytometry was performed using a FACS 
Canto Flow Cytometer (BD) and data was analysed using 
FlowJo software. The expression levels of activation 
markers are shown as the median fluorescence intensity 
(MFI).
In vivo dendritic cell migration
Inflamed back skin of mice was painted with 
fluorescein isothiocyanate (FITC - 0.5%, Thermo 
Scientific) dissolved in acetone/dibutyl phthalate 
(1:1 vol/vol - Sigma) as described [71, 72]. Eighteen 
hours later, inguinal and axillary lymph nodes were 
harvested, cellularity determined and the proportions of 
FITC+CD11c+CD11b+ cells were quantified (Schematic 
shown in Figure 2H) using flow cytometry.
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Quantitative RT- PCR
RNA was isolated as described in the Supplementary 
Methods. Gene expression was investigated by 
quantitative RT-PCR using FastStart Universal SYBR 
Green Master Mix (Roche), the 7900HT Fast Real-time 
PCR system (Life Technologies), and quantified using 
the 2-∆∆Ct method. Primers (Microsynth) are shown in 
Supplementary Methods Table 3. All data were normalized 
to the expression of the reference gene Rplp0. 
Generation of LEC-conditioned media
Human dermal lymphatic endothelial cells [73] were 
cultured on collagen coated (50 µg/mL) tissue culture 
plates in EBM (Lonza) + 20% FBS (Life Technologies), 
1x penicillin/streptomycin (Life Technologies), 2 mM 
L-glutamine (Life Technologies), 25 µg/ml cAMP (Sigma-
Aldrich), and 10 µg/ml hydrocortisone (Sigma-Aldrich), 
until approximately 80% confluent. Cells were washed 
twice with PBS and cultured for 72 hours in 1% FBS 
EBM ± 20 µM Celecoxib (Sigma). Harvested cell culture 
supernatants were centrifuged and supernatants stored at 
-80°C. 
In vitro dendritic cell assays
CD11c+ cells (BMDCs) were generated from bone 
marrow as described in the Supplementary Methods. 
BMDCs were plated in triplicate per treatment group into 
U-bottom 96 well plates at 2x105/well and stimulated for 
24 hours with IFN-γ (100 ng/mL) or TPA (20 ng/mL). 
Recombinant human VEGF-C (R&D) was used at 500 
ng/mL. When assessing the effects of LEC-CM, BMDCs 
were cultured in 96 well plate wells in 10 µL complete 
media, 10 µL 1% FBS EBM and 50 µL LEC-CM for 
FACS analysis. For RNA extraction, 5x106 BMDCs were 
plated into 24 well plates and incubated with complete 
EBM:LEC-CM (1:1). For transwell migration assays, 
BMDCs were incubated ± IFN-γ (100 ng/mL). The 
following day, 2×104 cells were seeded onto 24-well 
transwell inserts (pore size 5 µm, Corning), in triplicates. 
The medium in the bottom chamber consisted of 1% 
FBS EBM and 500 ng/mL VEGF-C (R&D) or 100 ng/
mL CCL21 (R&D). Cells were incubated for 4 hours, the 
lower chamber medium was removed and the cell number 
was quantified using flow cytometry and Accucheck 
counting beads (Invitrogen). 
Statistical analyses
Histological parameters were measured in a blinded 
fashion. All data are expressed as the mean ± SD as stated 
in the figure legends. Statistical significance was assessed 
using the two-tailed unpaired Student’s t test or Two-way 
ANOVA with Bonferroni’s multiple comparison test as 
stated in the figure legends. A value of p < 0.05 was taken 
to be statistically significant.
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